Pulmonary Fibrosis Clinical Trials

• Male or female ≥ 40 years of age at the time of Randomization.

• A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual interstitial pneumonia (UIP) or probable UIP.

• Percent predicted (pp) FVC ≥ 40% on Screening spirometry.

• Participants may enter the study whether or not they are receiving background nintedanib or pirfenidone therapy approved for the treatment of IPF, but not both concurrently.